[WEBINAR] Continuous ADC Conjugation
Date
October 23rd, 2026Webinar Overview
In this webinar, Eóin Bourke from APC's process development team demonstrates how an antibody-drug conjugate (ADC) conjugation step was transitioned from batch to continuous flow processing.
Discover how kinetic modelling, shear testing and computational fluid dynamics (CFD) informed reactor design, and how experimental validation and modelling established process performance during steady-state operation, start-up and pump-failure scenarios.
ADC conjugation brings together complex biologics and highly potent small molecules. Small variations in reaction time, temperature and mixing can affect drug-to-antibody ratio (DAR), product quality and process consistency. For fast reactions, conventional batch processing can introduce control challenges that become increasingly significant during scale-up.
Our Approach
APC combines small-molecule, biologics, analytical and HPAPI expertise at one site. Our in-house analytical capabilities include HIC for DAR determination, SEC for antibody integrity and RP-HPLC for free drug analysis. Our HPAPI facility is independently verified for safe operation at an occupational exposure limit of 0.1 µg/m³.
This integrated approach is supported by iAchieve®, our digital CMC platform, which connects experimental data, process conditions, analytical results and the scientific rationale behind development decisions.
For ADC programmes, iAchieve helps teams trace how conjugation parameters influence critical quality attributes, including DAR and product integrity. By preserving this knowledge across development activities, teams can investigate variability, make evidence-based scale-up decisions and transfer process understanding into manufacturing without reconstructing the development history.
Power Up Your Process Development Knowledge
Receive actionable process development insights and explore cutting edge process development news with great science delivered to your inbox every couple of months.